ENTROLATE

Main information

Trade name:
ENTROLATE 10 TAB

Active ingredient:
Diloxanide Furoate,Tinidazole

Available from:
Stadmed

Dosage:
500,300;MG

Pharmaceutical form:
TAB

Composition:
10

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

21-9-2018

Pending EC decision: Trelegy Ellipta, fluticasone furoate / umeclidinium / vilanterol, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

21-9-2018

Pending EC decision: Elebrato Ellipta, fluticasone furoate / umeclidinium / vilanterol, Opinion date: 20-Sep-2018

Europe - EMA - European Medicines Agency

18-9-2018

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

5-9-2018

Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 2, Authorised

Europe - EMA - European Medicines Agency

20-8-2018

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 16, Authorised

Europe - EMA - European Medicines Agency

20-8-2018

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 14, Authorised

Europe - EMA - European Medicines Agency

19-6-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Fluticasone furoate / umeclidinium bromide / vilanterol trifenatate, Therapeutic area: Pneumology-allergology

Europe - EFSA - European Food Safety Authority EFSA Journal

12-6-2018

Human medicines European public assessment report (EPAR): Trelegy Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 1, Authorised

Europe - EMA - European Medicines Agency

12-6-2018

Human medicines European public assessment report (EPAR): Elebrato Ellipta, fluticasone furoate / umeclidinium / vilanterol, Revision: 1, Authorised

Europe - EMA - European Medicines Agency

7-6-2018

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 15, Authorised

Europe - EMA - European Medicines Agency

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP): -, Indacaterol (acetate) / mometasone (furoate), Therapeutic area: Pneumology-allergology

Europe - EFSA - European Food Safety Authority EFSA Journal

30-5-2018

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 13, Authorised

Europe - EMA - European Medicines Agency

17-5-2018

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate / vilanterol, Revision: 12, Authorised

Europe - EMA - European Medicines Agency

6-11-2018

Trelegy Ellipta (GlaxoSmithKline Trading Services Limited)

Trelegy Ellipta (Active substance: fluticasone furoate/umeclidinium/vilanterol) - Centralised - 2-Monthly update - Commission Decision (2018)7416 of Tue, 06 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4363/WS/1369

Europe -DG Health and Food Safety

6-11-2018

Elebrato Ellipta (GlaxoSmithKline Trading Services Limited)

Elebrato Ellipta (Active substance: fluticasone furoate/umeclidinium/vilanterol) - Centralised - 2-Monthly update - Commission Decision (2018)7417 of Tue, 06 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4781/WS/1369

Europe -DG Health and Food Safety

3-7-2018